Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NTX-301 |
Synonyms | |
Therapy Description |
NTX-301 inhibits DNMT1, potentially leading to reduced tumor growth and improved survival (PMID: 35410412; J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS7077). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NTX-301 | NTX 301|NTX301 | DNMT1 inhibitor 4 | NTX-301 inhibits DNMT1, potentially leading to reduced tumor growth and improved survival (PMID: 35410412; J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS7077). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04851834 | Phase Ib/II | Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | Terminated | AUS | 0 |
NCT04167917 | Phase I | NTX-301 | NTX-301 in MDS/AML | Recruiting | USA | 0 |